Disclosed are a pharmaceutical composition for preventing or treating a respiratory disease, and health functional food, a food composition, and a quasi-drug composition for preventing and ameliorating a respiratory disease, each including, as active ingredients, a Lactobacillus plantarum KC3 strain and a Leonurus japonicus extract. The composition including the Lactobacillus plantarum KC3 strain (Accession No: KCTC13375BP) and the Leonurus japonicus extract as active ingredients according to an aspect has a defense effect against respiratory damage caused by air pollutants such as fine dust and can inhibit expression of IL-17A, TNF-α, and CXCL-1, thereby being able to effectively treat or prevent a respiratory disease including chronic obstructive pulmonary disease (COPD). In addition, the effect of the active ingredient combination above results in a synergistic inhibition or treatment effect on bronchial inflammation by the administration compared to the existing therapeutic effect of a respiratory inflammatory disease of each of the Leonurus japonicus extract and the lactic acid bacteria KC3. Thus, the present disclosure can be usefully utilized for the prevention or treatment of a respiratory disease.

Disclosed are a pharmaceutical composition for preventing or treating a respiratory disease, and health functional food, a food composition, and a quasi-drug composition for preventing and ameliorating a respiratory disease, each including, as active ingredients, a Lactobacillus plantarum KC3 strain and a Leonurus japonicus extract. The composition including the Lactobacillus plantarum KC3 strain (Accession No: KCTC13375BP) and the Leonurus japonicus extract as active ingredients according to an aspect has a defense effect against respiratory damage caused by air pollutants such as fine dust and can inhibit expression of IL-17A, TNF-α, and CXCL-1, thereby being able to effectively treat or prevent a respiratory disease including chronic obstructive pulmonary disease (COPD). In addition, the effect of the active ingredient combination above results in a synergistic inhibition or treatment effect on bronchial inflammation by the administration compared to the existing therapeutic effect of a respiratory inflammatory disease of each of the Leonurus japonicus extract and the lactic acid bacteria KC3. Thus, the present disclosure can be usefully utilized for the prevention or treatment of a respiratory disease.

Disclosed are a pharmaceutical composition for preventing or treating a respiratory disease, and health functional food, a food composition, and a quasi-drug composition for preventing and ameliorating a respiratory disease, each including, as active ingredients, a Lactobacillus plantarum KC3 strain and a Leonurus japonicus extract. The composition including the Lactobacillus plantarum KC3 strain (Accession No: KCTC13375BP) and the Leonurus japonicus extract as active ingredients according to an aspect has a defense effect against respiratory damage caused by air pollutants such as fine dust and can inhibit expression of IL-17A, TNF-α, and CXCL-1, thereby being able to effectively treat or prevent a respiratory disease including chronic obstructive pulmonary disease (COPD). In addition, the effect of the active ingredient combination above results in a synergistic inhibition or treatment effect on bronchial inflammation by the administration compared to the existing therapeutic effect of a respiratory inflammatory disease of each of the Leonurus japonicus extract and the lactic acid bacteria KC3. Thus, the present disclosure can be usefully utilized for the prevention or treatment of a respiratory disease.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson’s disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., LeonurusjaponicusHoutt, Capsicum annuum L., Lophatherum gracile Brongn, Cur-cuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson’s disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., LeonurusjaponicusHoutt, Capsicum annuum L., Lophatherum gracile Brongn, Cur-cuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson’s disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., LeonurusjaponicusHoutt, Capsicum annuum L., Lophatherum gracile Brongn, Cur-cuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar.